The Bell2Bell (B2B) Podcast

Bell2Bell’s latest podcast features Hugh Rogers, CEO and Director of life sciences technology accelerator XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT). During the interview with IBN’s Communications Director Jonathan Keim, Rogers offered an operational update, discussing the company’s most recent achievements and future plans. XPhyto Therapeutics recently obtained European approval and launched an effective 25-minute PCR (polymerase chain reaction) test for COVID-19, with an initial focus on the German market and several other initiatives underway.

“This is an exciting time for the company. We’ve taken this product from invention to prototype to validation to commercial approval in about ten months,” Rogers said. He explained that the company’s 25-minute COVID-19 RT-PCR test (Covid-ID Lab) sits between a rapid antigen test and a centralized automated high-throughput PCR, offering diagnostic quality, fast results and ease of administration at point of care, whether that is a medical clinic, a pharmacy, a cruise ship turnover or airport, or any mobile testing center.

Bell2Bell’s latest podcast features Hugh Rogers, CEO and Director of life sciences technology accelerator XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT). During the interview with IBN’s Communications Director Jonathan Keim, Rogers offered an operational update, discussing the company’s most recent achievements and future plans. XPhyto Therapeutics recently obtained European approval and launched an effective 25-minute PCR (polymerase chain reaction) test for COVID-19, with an initial focus on the German market and several other initiatives underway.

“This is an exciting time for the company. We’ve taken this product from invention to prototype to validation to commercial approval in about ten months,” Rogers said. He explained that the company’s 25-minute COVID-19 RT-PCR test (Covid-ID Lab) sits between a rapid antigen test and a centralized automated high-throughput PCR, offering diagnostic quality, fast results and ease of administration at point of care, whether that is a medical clinic, a pharmacy, a cruise ship turnover or airport, or any mobile testing center.

Bell2Bell’s latest podcast features Gregory Wagner, CEO of RYAH Group Inc. During the briefing, Wagner discussed the company’s goals and milestones in 2021, as well as providing an overview of RYAH’s business model and product offerings.

“The main item that we’re discussing is obviously our listing on the Canadian Securities Exchange (CSE), with our ticker being ‘RYAH’,” Wagner said. “It was quite a long journey through a reverse takeover (RTO) transaction. We are very pleased to have some of our shareholder have access to the electronic markets after being with us for so many years, and we’re excited for achieving the next chapter of the company’s history.”

Bell2Bell’s latest podcast features Gregory Wagner, CEO of RYAH Group Inc. During the briefing, Wagner discussed the company’s goals and milestones in 2021, as well as providing an overview of RYAH’s business model and product offerings.

“The main item that we’re discussing is obviously our listing on the Canadian Securities Exchange (CSE), with our ticker being ‘RYAH’,” Wagner said. “It was quite a long journey through a reverse takeover (RTO) transaction. We are very pleased to have some of our shareholder have access to the electronic markets after being with us for so many years, and we’re excited for achieving the next chapter of the company’s history.”

Bell2Bell’s latest podcast features Setti Coscarella, CEO of TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQX: TOBAF). During the briefing, Coscarella discussed the company’s alternative to cigarettes and vape products.

“TAAT is an alternative combustible cigarette. Basically, what we do is make a cigarette from a combination of different plants that does not include tobacco,” Coscarella explained. “One of the primary ingredients is hemp. What we have done is transform that hemp, so it behaves like tobacco when smoked. We created a product that is non-addictive, that still satiates smokers like a cigarette does and provides them with the experience and taste of a cigarette at a much more affordable price. From a value proposition, smokers will find our product to be significantly better than any cigarette on the market today.”

Bell2Bell’s latest podcast features Setti Coscarella, CEO of TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQX: TOBAF). During the briefing, Coscarella discussed the company’s alternative to cigarettes and vape products.

“TAAT is an alternative combustible cigarette. Basically, what we do is make a cigarette from a combination of different plants that does not include tobacco,” Coscarella explained. “One of the primary ingredients is hemp. What we have done is transform that hemp, so it behaves like tobacco when smoked. We created a product that is non-addictive, that still satiates smokers like a cigarette does and provides them with the experience and taste of a cigarette at a much more affordable price. From a value proposition, smokers will find our product to be significantly better than any cigarette on the market today.”

The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell’s latest podcast features Sean Dollinger, founder of PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF). During the briefing, Dollinger discussed PlantX’s business model and operating markets, as well as providing an introduction to the company’s seasoned management team.

“We’re the one-stop-shop for everything plant-based – meal deliveries, groceries, even plants for the home – we believe in a plant-based lifestyle, not just plant-based food. That’s really what we’re all about here,” Dollinger said. “We’re really forming a community around the whole plant-based [movement]. I’ve been on that journey for about 10 years and always felt judged when I was going through it, so really what we’re trying to do is form this community around making everybody feel welcomed. You want to be introduced to the plant-based space for one meal, one snack, a week, a year… we’re here for you.”

The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell’s latest podcast features Sean Dollinger, founder of PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF). During the briefing, Dollinger discussed PlantX’s business model and operating markets, as well as providing an introduction to the company’s seasoned management team.

“We’re the one-stop-shop for everything plant-based – meal deliveries, groceries, even plants for the home – we believe in a plant-based lifestyle, not just plant-based food. That’s really what we’re all about here,” Dollinger said. “We’re really forming a community around the whole plant-based [movement]. I’ve been on that journey for about 10 years and always felt judged when I was going through it, so really what we’re trying to do is form this community around making everybody feel welcomed. You want to be introduced to the plant-based space for one meal, one snack, a week, a year… we’re here for you.”

Bell2Bell’s latest podcast features Mel Engle, newly appointed CEO of Predictive Oncology Inc. (NASDAQ: POAI), as well as CFO Bob Myers and Mark Collins, Chief Technical Officer of the company’s Helomics subsidiary. During the briefing, Engle discussed his background before passing the microphone to Myers and Collins for updates on Predictive Oncology’s financial footing, current operations and goals for 2021.

“I’ve been on the board of Predictive Oncology for about four years, and, within the last year-and-a-half, I’ve been the Chairman of the Board,” Engle said. “Being in that kind of position, it’s easier for me to be able to step into this role… I’ve been a CEO of many companies beforehand, the most notable of which is a pharmaceutical company that was called Dey Laboratories, which was a subsidiary of Merck. We were a $610 million company when sold to Mylan back in 2007. That was a pharmaceutical respiratory company, so I’m very familiar with the ins-and-outs of R&D and the notion of what Predictive Oncology is doing.”

Engle is also currently on the board of WindGap Medical, a start-up focused on the development of an innovative EpiPen, and he previously served as CEO of cell separation company ThermoGenesis and orthobiologics firm Anika Therapeutics.

To hear the entire podcast and subscribe for future episodes, visit: https://podcast.bell2bell.com.

Bell2Bell’s latest podcast features Mel Engle, newly appointed CEO of Predictive Oncology Inc. (NASDAQ: POAI), as well as CFO Bob Myers and Mark Collins, Chief Technical Officer of the company’s Helomics subsidiary. During the briefing, Engle discussed his background before passing the microphone to Myers and Collins for updates on Predictive Oncology’s financial footing, current operations and goals for 2021.

“I’ve been on the board of Predictive Oncology for about four years, and, within the last year-and-a-half, I’ve been the Chairman of the Board,” Engle said. “Being in that kind of position, it’s easier for me to be able to step into this role… I’ve been a CEO of many companies beforehand, the most notable of which is a pharmaceutical company that was called Dey Laboratories, which was a subsidiary of Merck. We were a $610 million company when sold to Mylan back in 2007. That was a pharmaceutical respiratory company, so I’m very familiar with the ins-and-outs of R&D and the notion of what Predictive Oncology is doing.”

Engle is also currently on the board of WindGap Medical, a start-up focused on the development of an innovative EpiPen, and he previously served as CEO of cell separation company ThermoGenesis and orthobiologics firm Anika Therapeutics.

To hear the entire podcast and subscribe for future episodes, visit: https://podcast.bell2bell.com.